News

Christopher Bunick, MD, discusses the future progress of acne management—including a potential mRNA vaccine current in development.

New 16-week data from the SPROUT trial show the PDE4 inhibitor may be highly efficacious in chilren and adolescents.

The novel OX40 inhibitor showed significant efficacy in 4 different doses versus placebo in Fall Clinical Dermatology data.

With a broadening array of drug options, involving patients in the care process may be a key to adherence and long-term success.

Recent phase 3 trial results suggest positive effects and faster onset using CAL/BDP cream for adult plaque psoriasis.

Pooled data from 7 clinical trials show the IL-23 inhibitor is not associated with worsened risk of adverse events or infections.

Christopher Bunick, MD, PhD, reviews the benefit of antibiotic resistance, blood-brain barrier penetration, and digestive distress with agents like sarecycline.

Dermatologists and primary care physicians believe there is a significant unmet need for treatments for patients with mild or moderate atopic dermatitis.

Peter Lio, MD, shares his strategy for advancing severely impacted patients from systemic therapy to either upadacitinib or abrocitinib.

A discussion regarding the use of plaque psoriasis treatments such as apremilast, ixekizumab, and methotrexate.

A dermatologist considers what the orally-administered TYK2 inhibitor will provide eligible adult patients.

Data from the phase 3 LIMMitless show patients received long-term benefit from the biologic, regardless of baseline demographic or disease status.

Peter Lio, MD, explains firsthand how abrocitinib and upadacitinib became the latest options for his most difficult-to-treat patients.

Raj Chovatiya, MD, PhD, reviews the clinical progression of tapinarof and roflumilast cream headed into the 2022 Fall Clinical.

Data from NORD Breakthrough Summit 2022 support the need for exacerbation prevention among patients with bronchiectasis, a rare chronic condition.

The monitoring strategy used a self-operated artificial-intelligence–enabled home monitoring system in conjunction with standard care for early detection of nAMD.

The findings indicate a discrepancy between racial and ethnic demographic data in RCTs of DME and RVO and the 2010 US Census population.

Risk factors associated with inpatient mortality, included increasing age, ulcerative colitis, IBD-related surgery, pneumonia, chronic lung disease, acute kidney injury, malnutrition, frailty, heart failure, blood transfusion, sepsis/septic shock, and thromboembolism.

PASI 100 was achieved by 28% of patients in week 4, 89% in week 12, and 68% in week 36.

When compared to an intervention system guided by a therapist, a newly-designed self care system for atopic dermatitis patients may be as helpful.

Genetic factors previously known to predispose people to hyperopia were not risk factors for clinically significant depression in the study.

National coverage of MTMs for diet-related diseases may be associated with 1.6 million averted hospitalizations and net cost savings of $13.6 billion annually.

At 14 week, 33% of patients in the 210 mg induction etrolizumab group were in clinical remission, compared to 29% of the placebo induction group.

Approximately 5% of nurses in Mozambique were infected with hepatitis B virus during a 3-month period in 2020.

Dr. Chopra described several key points of his Pri-Med Midwest presentation regarding the future of advances in medicine, including artificial intelligence, gut bacteria, and CRISPR technology.

Top-line data comparing 2 strains of a non-systemically absorbed drug candidate was announced this morning, with SYNB1934 expected to advance to a phase 3 clinical trial.

A study featured at CHEST 2022 investigated INCS in children with OSAS to determine if the therapy improved their symptoms, polysomnography findings, behavior, and quality of life.

New analyses suggest insomnia symptoms among older patients may play a pivotal role in the relationship between objective and self-reported cognition.

The emergence of weight loss agents like tirzepatide and an FDA Fast Track designation announced days earlier, endocrinologists were excited to discuss what's happening at Pri-Med Midwest 2022.

Study data show 64.3% of patients self-administering etripamil converted to sinus rhythm within 30 minutes compared to 31.2% on placebo.